Progenics Pharma (PGNX) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results
May 5, 2016 7:31 AM EDTOn May 2nd, the Company Announced It Had Granted Exclusive World-Wide Rights to Bayer to Develop and Commercialize Products Using Progenics PSMA Antibody Technology In Combination with Alpha-Emitting RadionuclidesEnrollment in Pivotal Phase 3 Study of PSMA-Targeted SPECT/CT Imaging Agent 1404 Ongoing in the U.S. and CanadaPyL Study Data to be Presented at the 2016 American Urological AssociationAZEDRA® Pivotal Phase 2b Trial Topline Results Expected Between December 2016 and March 2017On April 4th, Oral RELISTOR® PDUFA Date Was Set for July 19, 2016; Approval to Trigger $50 Million Milestone Payment from Valeant plus Royalties and Sales... More
